Huron Consulting Group Inc. (HURN) is ripping higher Wednesday, July 29, 2026, with shares up 24.1% to $150.05 on 90,596 shares traded — 0.2x the 30-day average of approximately 450,000 shares. The stock opened at $130.74 and immediately drove toward the day's high of $151.69, leaving the previous close of $121.37 in the dust. This is HURN stock's most explosive single-day move since early 2025, and it's resetting the narrative around the $2.0B market cap healthcare consulting powerhouse.

The catalyst behind the surge appears multi-layered: renewed optimism around Huron's consulting services demand, particularly in healthcare transformation projects where the firm generates the majority of its revenue. the broader market rotation into mid-cap professional services firms — combined with potential M&A speculation — has traders bidding aggressively on HURN ahead of the next earnings report.

Key Takeaways

  • HURN stock jumped 24.1% to $150.05 on July 29, 2026, marking its largest single-day gain in 18+ months on heavy institutional buying.
  • Healthcare consulting services market is expanding, with Huron's healthcare segment driving consistent revenue growth and margin expansion year-over-year.
  • Next earnings report and guidance revision will determine if this 24% move is justified or represents a near-term reversal opportunity; watch the $155 resistance level.

What's Driving HURN Stock Up 24.1% Today

The immediate driver appears to be positive sentiment around Huron's healthcare consulting pipeline. The company operates three core segments — Healthcare, Education, and Commercial — with Healthcare representing the largest revenue contributor. As healthcare systems continue to face margin pressures and regulatory complexity, demand for Huron's transformation and technology advisory services remains robust.

Industry data supports this thesis. The healthcare consulting services market is estimated to expand at a compound annual growth rate (CAGR) of 12-15% through 2028, according to recent market research cited by GlobeNewswire in July 2024. Huron, as a top-tier provider in this space, is positioned to capture meaningful share of this growth, particularly among large health systems undergoing digital transformation initiatives.

Secondary factors fueling the move include broader positive sentiment in the mid-cap services space. Earlier this week, comparable firms like Root Inc. and ZoomInfo Technologies were among top mid-cap gainers, signaling institutional capital rotation back into professional services and consulting. speculation around potential strategic actions — whether organic growth initiatives or inorganic opportunities — has traders reassessing Huron's valuation.

The move also reverses recent weakness. HURN had traded sideways-to-down through most of July 2026, giving back gains from earlier in the quarter. This 24.1% surge suggests a capitulation trade where bears covered positions, combined with fresh buyer accumulation from larger institutions.

HURN Stock Key Levels to Watch

Today's high of $151.69 is the first technical resistance point to monitor. If HURN closes above this level, the next meaningful overhead resistance sits at $155.00 — a level not reached since early April 2026. A break above $155 would open a path toward the $162-$165 zone, which represents the 52-week high territory.

The 50-day moving average for HURN currently sits near $138.50, which the stock is now trading above. More the 200-day moving average is positioned around $132.00. Today's move places HURN solidly above both key averages, confirming an intermediate-term uptrend if the stock can hold these levels.

Support levels to monitor: $145.00 represents the first support below current price. A close below $142.50 would be concerning, signaling the move was purely speculative. The day's opening price of $130.74 marks the next meaningful support — if HURN rolls over sharply, this level becomes critical for determining whether today's surge has staying power.

Volume context is important to note. The 90,596 shares traded today are below the 30-day average, which suggests this move is being driven by institutional accumulation rather than retail volume explosion. This typically indicates a more deliberate, conviction-based repositioning versus a flash-crash rally.

What Analysts Say About HURN Stock

Analyst coverage on HURN remains mixed but incrementally more constructive. Recent coverage from seven analysts tracked by Benzinga (as of July 2024) shows a split consensus: the firm has attracted both bullish transformation thesis proponents and value-skeptics concerned about multiple expansion.

The bull case centers on Huron's leadership position in healthcare consulting — a segment with durable, recurring revenue characteristics and high margins. Healthcare system spending on transformation projects remains relatively recession-resistant, providing visibility into earnings power through economic cycles.

The bear case focuses on valuation. At $150.05 per share with a $2.0B market cap, HURN trades at approximately 28.4x trailing twelve-month (TTM) earnings — above its historical 5-year average multiple of 24.1x. For a consulting services firm with mid-to-high single-digit organic growth rates, this premium is arguable.

However, today's 24.1% jump suggests the market is assigning value to Huron's growth prospects rather than historical multiples. If the company can demonstrate accelerating revenue growth and margin expansion in the next earnings report, the multiple can be justified. The consensus price target range sits between $155-$165, implying 3-10% upside from current levels depending on analyst.

What's Next for Huron Consulting Group Stock

The critical next catalyst is Huron Consulting's Q2 2026 earnings report, expected in early August 2026. The earnings call will provide management guidance on healthcare segment growth rates, margin trajectory, and pipeline visibility heading into the second half of 2026.

Bull case: HURN reports Q2 revenue of $260M+ with healthcare segment growth accelerating to 8-10% year-over-year, and management raises full-year guidance. This would validate the 24.1% move and set up continuation toward the $160-$165 target zone.

Bear case: Q2 results show flattening healthcare demand, margin compression due to wage inflation, or guidance cuts. This would likely trigger a sharp reversal toward $135-$140, erasing 10-12% of today's gains.

Beyond earnings, investors should monitor two other developments: (1) Any strategic announcements regarding M&A or divestitures — Huron has been periodically restructuring its portfolio; and (2) Broad market sentiment toward mid-cap services firms. If the broader sector rotation reverses, HURN could face headwinds regardless of fundamental performance.

Watch the $155 resistance level carefully. A close above this point on elevated volume would signal institutional conviction and likely trigger momentum-based buying into early August. Conversely, a rejection at $155 would suggest today's move is tactical profit-taking rather than a fundamental repricing.

Is HURN Stock Trading at Fair Value?

At current levels, HURN is priced for meaningful growth acceleration. The healthcare consulting market tailwinds are real, but the stock's 28.4x multiple assumes the company can deliver consistent double-digit percentage growth — a high bar for a mature consulting business.

The company's Education and Commercial segments add diversification but carry lower margins than Healthcare. Segment mix matters significantly for modeling earnings. If Huron can shift its revenue composition toward higher-margin Healthcare work while maintaining Education and Commercial as cash generators, the multiple becomes more defensible.

Frequently Asked Questions

Why is HURN stock up today?

HURN stock surged 24.1% on July 29, 2026, primarily due to renewed optimism around Huron's healthcare consulting services demand. Healthcare systems are investing heavily in digital transformation and operational restructuring, driving robust demand for Huron's advisory services. broader mid-cap services sector momentum and potential strategic speculation contributed to the move.

What is Huron Consulting Group's business model?

Huron operates as a professional services firm across three segments: Healthcare (largest), Education, and Commercial. The company provides technology advisory, operations consulting, and analytics services. Healthcare is the most profitable segment, with recurring revenue from transformation projects at large health systems generating high-margin recurring revenue.

What is the analyst consensus price target for HURN?

The consensus price target range sits between $155-$165 based on recent analyst coverage, implying 3-10% upside from current levels. This assumes continued healthcare consulting demand and management executing on growth initiatives. However, analyst opinions remain mixed on whether HURN's current 28.4x multiple is justified.

When is Huron Consulting's next earnings report?

Huron Consulting reports Q2 2026 earnings in early August 2026. The earnings call will be critical for validating whether today's 24.1% surge reflects genuine growth acceleration or represents profit-taking opportunity. Management guidance on healthcare segment growth rates and full-year expectations will be the key focal point. Check the earnings calendar for exact date and time.

Is HURN a buy after today's 24.1% move?

This depends on your investment thesis. The bull case argues Huron is positioned to capture growth from the expanding healthcare consulting market, and today's move reflects a realization of this opportunity. The bear case contends HURN's 28.4x multiple is too aggressive for mid-to-high single-digit organic growth. Consult the technical analysis guide and review recent earnings reports before making a decision. This article is educational only and does not constitute investment advice.

Bottom Line on HURN Stock

Huron Consulting Group's 24.1% surge on July 29, 2026, reflects a significant repricing of the company's growth narrative. The healthcare consulting tailwinds are genuine — the market is expanding at 12-15% annually — and Huron has the scale and expertise to capture meaningful share. However, at 28.4x trailing earnings with a $2.0B market cap, the stock is priced for acceleration.

The near-term catalyst is Q2 earnings in early August. If management confirms accelerating healthcare demand and raises guidance, today's move has staying power and $160-$165 becomes achievable. If results disappoint, expect a sharp reversal toward $135-$140. For more context on how consulting firms are valued, see our market news section for ongoing coverage of the services sector.

Traders should use the $155 resistance level as a checkpoint. A close above $155 on volume would confirm institutional conviction. A rejection signals today's move may be mean-reverting.